14 June 2022

Compulsory licensing for expensive medicines

Out now: Our 200 pp. law & economics study on compulsory licensing (CLs) for very expensive medicines commissioned by the Belgian KCE - Federaal Kenniscentrum voor de Gezondheidszorg - Centre Fédéral d'Expertise des Soins de Santé . We stress that a modernized, well-governed system for more effective CLs can remain an essential tool. But it should still be used with care in extraordinary circumstances & on a case by case basis. Morever, we highlight the need for more transparency and that other mechanisms must be considered & optimized too.

The report is written in English and was drafted in response to a Belgian legislative proposal. Yet, in light of recent developments and the challenges that we are facing, it is definitely also relevant beyond the Belgian context. In particular also in the context of the current interest of the European Commission in CLs.

So many thanks to all contributors, stakeholder-representatives and evaluators that have been involved in the process.

Citation: Esther van Zimmeren, Timo Minssen, Liesbet Paemen, Walter Van Dyck, Jeroen Luyten, Rosanne Janssens, Liese Barbier Steven Simoens, Céline Pouppez, Irina Cleemput, Imgard Vinck: Compulsory licensing for expensive medicines. Health Services Research (HSR). Brussels. Belgian Health Care Knowledge Centre (KCE). 2022. KCE Reports 356. D/2022/10.273/35.

Universiteit Antwerpen, Københavns Universitet - University of Copenhagen, KADOC-University of Leuven , Ohad Graber-Soudry , CeBIL , University of Copenhagen, Faculty of Law

Click here to see the full study